The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) ...

On top of all that, young people’s cancers tend to be more aggressive, often because they’re diagnosed at later stages. Colon ...

Radiation therapy may account for half of all new cancers among the growing population of childhood cancer survivors, according to a study published Aug. 11 in the Journal of Clinical Oncology. With ...

The "off-the-shelf" vaccine has also shown promising results for pancreatic cancer. Since the U.S. Preventive Services Task Force (USPSTF) changed its recommendation for when Americans at average risk ...

Yue Liao contributes to City of Hope article on wearable sensors and detecting or preventing long-term health risks ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

A researcher at The University of Texas at Arlington is helping a leading national cancer center explore how wearable devices could help childhood cancer survivors avoid long-term health complications ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results ...

A researcher at The University of Texas at Arlington is helping a leading national cancer center explore how wearable devices could help childhood ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

The FDA has granted accelerated approval to Hernexeos for the treatment of adults with unresectable or metastatic non-squamous NSCLC.

Accelerated approval was based on results from the Phase Ib Beamion-LUNG 1 trial (NCT04886804), which showed a 75% objective ...